Lorianne Masuoka

Learn More
Recent advances in clinical neurophysiology of epilepsy have enhanced our ability to study the epileptogenic region and have improved the localization of seizures in patients with intractable epilepsy. Computed spike analyses using electroencephalogram or magnetoencephalography superimposed on magnetic resonance images define precise relationships between(More)
Naloxegol (previously known as NKTR-118) is a peripherally acting μ-opioid receptor antagonist engineered using polymer conjugate technology in development as an oral, once-daily agent for the treatment of opioid-induced constipation (OIC). Eligible patients with OIC (n=207), defined as <3 spontaneous bowel movements (SBMs) per week with accompanying(More)
The purpose of this study was to examine the relationship between patient management strategies employed by study personnel, and patient retention and adherence to treatment in the first year of a Phase III clinical trial of interferon beta-1b for treatment of secondary progressive multiple sclerosis (MS). Study staff from each of 35 sites were interviewed(More)
5047 Background: NKTR-102, a topoisomerase-I inhibitor-polymer conjugate with markedly reduced peak concentrations and a continuous concentration profile, demonstrated broad antitumor activity per RECIST in a phase I study. The original phase 2 study in platinum-resistant/refractory ovarian cancer showed a 21% confirmed objective response rate (ORR)(More)
1034 Background: NKTR-102 is a topoisomerase I inhibitor-polymer conjugate with reduced peak concentration and a continuous concentration profile. METHODS This was an open-label phase II study in MBC pts following PD on a taxane; pts were randomized to NTKR-102 given IV at 145 mg/m2 over 90-min every 14 or 21 days. Primary endpoint: ORR by RECIST v1.0;(More)
269 Background: NKTR-102 is a topoisomerase I inhibitor-polymer conjugate with reduced peak concentration and a continuous concentration profile. METHODS This was an open-label phase II study in MBC pts following PD on a taxane (T). Pts were randomized to NKTR-102 given IV at 145 mg/m2 over 90-min every 14 or 21 days. Efficacy endpoints included ORR by(More)
The pathophysiological sequelae of the primary spinal cord injury (SCI) include edema, spinal cord swelling, reduced blood flow, and local tissue ischemia resulting in further cellular necrosis culminating in the appearance of a tissue void (cavity). Biodegradable scaffolds can be implanted within the necrotic lesion to fill this void and provide structural(More)
  • 1